PROGRAMME

EU-X-CT PUBLIC STAKEHOLDERS' FORUM

MAKING CROSS-BORDER ACCESS TO CLINICAL TRIALS A REALITY

12 April 2024

10:00 – 17:00 CEST

Crowne Plaza Brussels Airport
Da Vincilaan 4
1831 Diegem

> REGISTER HERE <

WEBSITE

EU-X-CT C/O EFGCP
EU-X-CT Page

Follow us on LinkedIn

INTRODUCTION

The pan-European public-private EU-X-CT Initiative aims at facilitating cross-border access to clinical trials in concrete terms. We are collecting information on the regulatory, ethical, social security and organizational conditions for the involved stakeholders, experiences and best practices in all European countries. This Public Stakeholder Forum will be the opportunity to jointly review the national conditions for patients, clinical investigators, academia/public funders and industry sponsors in need for cross-border participation of patients in clinical trials. The EU-X-CT gap analysis will be the basis for our panel and open forum discussions to come to conclusions about most efficient European and national strategies and activities for improvements in the near and mid-term future.

PROGRAMME COMMITTEE

Bettina Ryll	Stockholm School of Economics Institute for Research	Sweden
Emilie Prazakova	Roche	Czech Republic
Ingrid Klingmann	EFGCP	Belgium
Lisbeth Oxholm Snede	Patient advocate	Denmark
Maja Pizevska	Berlin Institute of Health	Germany
Marén Koban	Merck Healthcare KGaA	Germany
Sabine Kläger	ECRIN	Germany
Solange Corriol-Rohou	AstraZeneca	France
Teodora Lalova-Spinks	KU Leuven	Belgium

ACKNOWLEDGEMENT

THE EU-X-CT THANKS ITS CONTRIBUTORS FOR THEIR CONTINUED SUPPORT

INITIATIVE LEADERSHIP

EFCCP

efpia

12 APRIL, 2024 - CEST

SCHEDULE

09:00 **Registrations & Welcome Networking Coffee**

SESSION 1: WHERE ARE WE TODAY?

10:00 **Introduction to EU-X-CT**

Welcome from the industry members
Welcome from the academia members
Welcome from the patient members

10:20 **Round table: Patient experience**

Moderator(s):
Lisbeth Oxholm Snede, *Founder of Patients Unite*

10:50 **Keynote: Overcoming borders will make Europe a more attractive place for clinical trials**

EU Commission DG R&I

Discussion

11:20 **The issues of cross-border access to clinical trials in Europe: The EU-X-CT gap analysis**

Moderator(s):
Susan Bhatti, *Merck Group*

12:20 **Panel and Open Forum Discussion:**

- Is this picture accurate and comprehensive?
- Where are the assessment gaps?
- How to close them?
- Which other EU partnerships suffer from the lack of cross-border access to clinical trials?

Moderator(s):
Solange Corriol-Rohou, *AstraZeneca*

13:00 **Lunch**

SESSION 2: WHERE DO WE WANT TO GO?

14:00 **European needs in overcoming borders in clinical research**

Cross-border access in precision medicine trials: PCM4EU and PRIME-ROSE

Moderator(s):
Sabine Kläger, *ECRIN*

14:30 **The way forward: How do we make progress in cross-border access to Clinical Trials?**

Moderator(s):
Bettina Ryll, *Stockholm School of Economics Institute for Research*

Panel and Open Forum Discussion

15:30 **Break**

15:50 **Open Forum Discussion: How can EU-X-CT achieve the most urgent goals and how to make them sustainable?**

Moderator(s):
Ingrid Klingmann, *EFGCP*

16:50 **Conclusions and next steps**

Ingrid Klingmann, *EFGCP*

17:00 **End of meeting**